Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

EY Entrepreneur of the year 2025

Shorla Co-Founders – EY Entrepreneur of the Year 2025 Finalists

July 17th 2025June 5th 2025

Read More

ASCO Annual Meeting

Shorla Oncology Participates in ASCO 2025

July 17th 2025May 31st 2025

Read More

Great Place To Work Certification

Shorla Receives Great Place to Work Certification 2025

July 17th 2025May 2nd 2025

Read More

Tepylute

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

July 17th 2025April 29th 2025

Read More

Shorla Oncology attending Asembia 2025

Shorla Oncology is attending AXS25 SUMMIT April 27 – May 1, 2025

April 23rd 2025

Read More

PCMA Meeting

Shorla Oncology is attending the PCMA Annual Meeting March 10-11 2025

July 17th 2025March 10th 2025

Read More

Milan

Audrene Rice, Our R&D Pipeline and Portfolio Manager, is attending  Bio-Europe from March 17-19 in Milan, Italy

March 10th 2025

Read More

BW

Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams

March 4th 2025March 4th 2025

Read More

GPTW

We are delighted to be recognised as a Best Workplace by Great Place to Work

February 27th 2025February 27th 2025

Read More

Older posts
Newer posts
Page1 Page2 Page3 … Page13
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.